Journal of Clinical Pediatrics >
Examination of peripheral blood MDSCs quantitative variations and biological properties in infants with necrotizing enterocolitis: utilizing GEO database insights
Received date: 2024-04-15
Accepted date: 2024-05-20
Online published: 2025-02-12
Objective To investigate the correlation between peripheral blood myeloid-derived suppressor cells (MDSCs) levels and the severity of necrotizing enterocolitis (NEC), and the biological characteristics of MDSCs in NEC infants. Methods The single-cell sequencing dataset of peripheral blood from NEC patients was downloaded from the GEO database and analysed by quality control, batch correction, clustering dimensionality reduction and cell type annotation. The number and proportion of MDSCs in the peripheral blood of NEC patients at different disease stages were calculated. Subsequently, MDSCs subsets were extracted, differentially expressed genes and enrichment pathways were analysed, and the expression of MDSC immunosuppressive function, apoptosis and chemotaxis related molecules were compared. Results As the severity of NEC increased, the corresponding number and proportion of MDSCs gradually decreased. Compared with stage II NEC patients, upregulated genes in MDSCs of stage III NEC patients were enriched in multiple pathways, such as positive regulation of leukocyte activation and negative regulation of locomotion. And there was no significant difference in immunosuppressive function and apoptotic pathway activation between MDSCs from stage II and III NEC patients, whereas the expression of chemokine receptor CXCR1 was significantly decreased in MDSCs from stage III NEC patients. Conclusion The number of MDSCs in the peripheral blood of NEC patients was inversely correlated with the severity of NEC. And the reduction of MDSCs in stage III NEC patients could be attributed to the downregulated expression of CXCR1.
Key words： necrotizing enterocolitis; myeloid-derived suppressor cells; CXCR1; child
LE Huijuan , WU Jin . Examination of peripheral blood MDSCs quantitative variations and biological properties in infants with necrotizing enterocolitis: utilizing GEO database insights[J]. Journal of Clinical Pediatrics, 2025 , 43(2) : 112 -119 . DOI: 10.12372/jcp.2025.24e0366
| [1] | Neu J, Walker WA. Necrotizing enterocolitis[J]. N Engl J Med, 2011. 364(3): 255-264. |
| [2] | Nino DF, Sodhi CP, Hackam DJ. Necrotizing enterocolitis: new insights into pathogenesis and mechanisms[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(10): 590-600. |
| [3] | He YM, Li X, Perego M, et al. Transitory presence of myeloid-derived suppressor cells in neonates is critical for control of inflammation[J]. Nat Med, 2018, 24(2): 224-231. |
| [4] | Ibrohim IS, Pratama HA, Fauzi AR, et al. Association between prognostic factors and the clinical deterioration of preterm neonates with necrotizing enterocolitis[J]. Sci Rep, 2022, 12(1): 13911. |
| [5] | Das A, Ariyakumar G, Gupta N, et al. Identifying immune signatures of sepsis to increase diagnostic accuracy in very preterm babies[J]. Nat Commun, 2024, 15(1): 388. |
| [6] | Alshetaiwi H, Pervolarakis N, McIntyre LL, et al. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics[J]. Sci Immunol, 2020, 5(44): eaay6017. |
| [7] | Ghaebi M, Nouri M, Ghasemzadeh A, et al. Immune regulatory network in successful pregnancy and reproductive failures[J]. Biomed Pharmacother, 2017, 88: 61-73. |
| [8] | Fainaru O, Hantisteanu S, Hallak M. Immature myeloid cells accumulate in mouse placenta and promote angiogenesis[J]. Am J Obstet Gynecol, 2011, 204(6): 544.e18-544.e23. |
| [9] | Pan T, Liu Y, Zhong LM, et al. Myeloid-derived supp-ressor cells are essential for maintaining feto-maternal immunotolerance via STAT3 signaling in mice[J]. J Leukoc Biol, 2016, 100(3): 499-511. |
| [10] | Kang X, Zhang X, Liu Z, et al. CXCR2-mediated granulocytic myeloid-derived suppressor cells' functional characterization and their role in maternal fetal interface[J]. DNA Cell Biol, 2016, 35(7): 358-365. |
| [11] | Pan T, Zhong L, Wu S, et al. 17β-Oestradiol enhances the expansion and activation of myeloid-derived suppressor cells via signal transducer and activator of transcription (STAT)-3 signalling in human pregnancy[J]. Clin Exp Immunol, 2016, 185(1): 86-97. |
| [12] | Kang X, Zhang X, Liu Z, et al. Granulocytic myeloid-derived suppressor cells maintain feto-maternal tolerance by inducing Foxp3 expression in CD4+CD25-T cells by activation of the TGF-β/β-catenin pathway[J]. Mol Hum Reprod, 2016, 22(7): 499-511. |
| [13] | Ostrand-Rosenberg S, Sinha P, Figley C, et al. Frontline science: myeloid-derived suppressor cells (MDSCs) facilitate maternal-fetal tolerance in mice[J]. J Leukoc Biol, 2017, 101(5): 1091-1101. |
| [14] | Liu Y, Perego M, Xiao Q, et al. Lactoferrin-induced myeloid-derived suppressor cell therapy attenuates pathologic inflammatory conditions in newborn mice[J]. J Clin Invest, 2019, 129: 4261-4275. |
| [15] | Liu Y, Fatheree NY, Dingle BM, et al. Lactobacillus reuteri DSM 17938 changes the frequency of Foxp3+ regulatory T cells in the intestine and mesenteric lymph node in experimental necrotizing enterocolitis[J]. PLoS One 2013, 8, e56547. |
| [16] | Dingle BM, Liu Y, Fatheree NY, et al. FoxP3+ regulatory T cells attenuate experimental necrotizing enterocolitis[J]. PLoS One 2013, 8: e82963. |
| [17] | Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age[J]. Nat Immunol, 2018 19(2): 108-119. |
| [18] | Li BH, Garstka MA, Li ZF. Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor[J]. Mol Immunol, 2020, 117: 201-215. |
| [19] | Murphy PM, Tiffany HL. Cloning of complementary DNA encoding a functional human interleukin-8 receptor[J]. Science, 1991, 253(5025): 1280-1283. |
| [20] | Che J, Song R, Chen B, et al. Targeting CXCR1/2: The medicinal potential as cancer immunotherapy agents, antagonists research highlights and challenges ahead[J]. Eur J Med Chem, 2020, 185: 111853. |
| [21] | Greene S, Robbins Y, Mydlarz WK, et al. Inhibition of MDSC trafficking with SX-682, a CXCR1/2 inhibitor, enhances NK-cell immunotherapy in head and neck cancer models[J]. Clin Cancer Res, 2020, 26(6): 1420-1431. |
| [22] | Teijeira á, Garasa S, Gato M, et al. CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity[J]. Immunity, 2020, 52(5): 856-871. |
| [23] | Grutkoski PS, Graeber CT, D'Amico R, et al. Regulation of IL-8RA (CXCR1) expression in polymorphonuclear leukocytes by hypoxia/reoxygenation[J]. J Leukoc Biol, 1999, 65(2): 171-178. |
| [24] | Qin H, Zhuang W, Liu X, et al. Targeting CXCR1 alleviates hyperoxia-induced lung injury through promoting glutamine metabolism[J]. Cell Rep, 2023, 42(7): 112745. |
/
| 〈 |
|
〉 |
